Immunome (IMNM) financial statements
Immunome reported revenue of $7M in fiscal 2025, down 29.6% a year over 2 years.
Net income was -$212M.
Free cash flow was -$201M.
The diluted share count rose 7885% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Immunome's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $14M | $9M | $7M |
| Research and development | $9M | $7M | $14M | $23M | $23M | $130M | $177M |
| Selling, general and admin | $2M | $5M | $11M | $14M | $20M | $33M | $44M |
| Operating income | -$10M | -$12M | -$25M | -$37M | -$110M | -$306M | -$224M |
| Interest expense | $46,000 | $21,000 | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$10M | -$18M | -$25M | -$37M | -$107M | -$293M | -$212M |
| EPS (diluted) | -$9.55 | -$5.26 | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Diluted shares | 1M | 3M | 12M | 12M | 20M | 59M | 87M |
| Operating margin | — | — | — | — | -781.4% | -3382.4% | -3228.8% |
| Net margin | — | — | — | — | -761.9% | -3240.4% | -3060.0% |
Balance sheet
Fiscal years, from Immunome's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $3M | $40M | $49M | $20M | $138M | $217M | $653M |
| Total current assets | $3M | $43M | $57M | $23M | $145M | $221M | $661M |
| Property, plant and equipment | $2M | $2M | $855,000 | $681,000 | $2M | $10M | $15M |
| Total assets | $5M | $45M | $58M | $24M | $149M | $240M | $683M |
| Total current liabilities | $2M | $3M | $10M | $7M | $22M | $54M | $45M |
| Long-term debt | — | $134,000 | — | — | — | — | — |
| Total liabilities | $2M | $3M | $10M | $7M | $29M | $59M | $49M |
| Shareholders' equity | -$36M | $41M | $48M | $17M | $120M | $181M | $634M |
| Net debt | -$3M | -$39M | -$49M | -$20M | -$99M | -$143M | -$653M |
Cash flow
Fiscal years, from Immunome's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10M | -$12M | -$18M | -$29M | -$8M | -$111M | -$191M |
| Capital spending | $233,000 | $586,000 | $79,000 | $248,000 | $831,000 | $7M | $10M |
| Free cash flow | -$10M | -$13M | -$18M | -$29M | -$8M | -$118M | -$201M |
| Stock-based compensation | $14,000 | $621,000 | $3M | $5M | $6M | $16M | $26M |
| Net borrowing | — | $500,000 | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | -59.9% | -1304.8% | -2890.1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IMNM.
Open IMNM in InvestinglyQuestions
What was Immunome's revenue in 2025?
$7M in fiscal 2025, from its 10-K filing.
How much free cash flow does Immunome generate?
-$201M in fiscal 2025 (operating cash flow minus capital spending).
From Immunome's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.